Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice.

de la Cour, Charlotta; Lindqvist, Andreas; Egecioglu, Emil; Tung, Yc Loraine; Surve, Vikas; Ohlsson, Claes; Jansson, John-Olov; Erlanson-Albertsson, Charlotte; Dickson, Suzanne; Håkanson, Rolf

Published in:
Gut

DOI:
10.1136/gut.2004.058578

2005

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice

C Dornonville de la Cour, A Lindqvist, E Egecioglu, Y C L Tung, V Surve, C Ohlsson, J-O Jansson, C Erlanson-Albertsson, S L Dickson and R Håkanson

Gut 2005;54;907-913; originally published online 21 Apr 2005; doi:10.1136/gut.2004.058578

Updated information and services can be found at: http://gut.bmjournals.com/cgi/content/full/54/7/907

These include:

Data supplement
“Competing interest statement”
http://gut.bmjournals.com/cgi/content/full/gut.2004.058578/DC1

References
This article cites 47 articles, 19 of which can be accessed free at:
http://gut.bmjournals.com/cgi/content/full/54/7/907#BIBL

2 online articles that cite this article can be accessed at:
http://gut.bmjournals.com/cgi/content/full/54/7/907#otherarticles

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Stomach and duodenum (565 articles)
Basic sciences (526 articles)
Nutrition and Metabolism (1231 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Gut go to:
http://www.bmjjournals.com/subscriptions/
Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice

C Dornonville de la Cour, A Lindqvist, E Egecioglu, Y C L Tung, V Surve, C Ohlsson, J-O Jansson, C Erlanson-Albertsson, S L Dickson, R Håkanson

See end of article for authors’ affiliations

Correspondence to:
Professor R Håkanson,
Department of Pharmacology, Institute of Physiological Sciences,
University of Lund, BMC F13, S-221-84 Lund,
Sweden; rolf.hakanson@farm.lu.se

Revised version received
13 March 2005
Accepted for publication
22 March 2005
Published Online First
21 April 2004


Background and aims: The gastric hormone ghrelin has been reported to stimulate food intake, increase weight gain, and cause obesity but its precise physiological role remains unclear. We investigated the long term effects of gastrectomy evoked ghrelin deficiency and of daily ghrelin injections on daily food intake, body weight, fat mass, lean body mass, and bone mass in mice.

Methods: Ghrelin was given by subcutaneous injections (12 nmol/mouse once daily) for eight weeks to young female mice subjected to gastrectomy or sham operation one week previously.

Results: Gastrectomy reduced plasma concentrations of total ghrelin (octanoylated and des-octanoylated) and active (octanoylated) ghrelin by ~80%. Immediately after injection of ghrelin, the plasma concentration was supraphysiological and was still elevated 16 hours later. Daily food intake was not affected by either gastrectomy or ghrelin treatment. The effect of ghrelin on meal initiation was not studied. At the end point of the study, mean body weight was 15% lower in gastrectomised mice than in sham operated mice (p<0.001); daily ghrelin injections for eight weeks partially prevented this weight loss. In sham operated mice, ghrelin had no effect on body weight. The weight of fat was reduced in gastrectomised mice (~30%; p<0.01). This effect was reversed by ghrelin, enhancing the weight of fat in sham operated mice also (+20%; p=0.05). Gastrectomy reduced lean body mass (~10%; p<0.01) and bone mass (~20%; p<0.001) compared with sham operated mice. Ghrelin replacement prevented the gastrectomy induced decrease in lean body mass but did not affect bone. In sham operated mice, ghrelin affected neither of these two parameters.

Conclusions: Ghrelin replacement partially reversed the gastrectomy induced reduction in body weight, lean body mass, and body fat but not in bone mass. In sham operated mice, ghrelin only increased fat mass. Our results suggest that ghrelin is mainly concerned with the control of fat metabolism and that ghrelin replacement therapy may alleviate the weight loss associated with gastrectomy.

The peptide hormone ghrelin is produced by A-like cells in the acid producing part of the stomach but small amounts also occur further down in the digestive tract and in the pancreas.1-4 In addition, there are reports of ghrelin immunoreactive neurones in the hypothalamus.5-7 Ghrelin was discovered by virtue of its ability to stimulate Ca2+ entry in a cell line expressing the growth hormone secretagogue (GHS) receptor. Subsequently, ghrelin was shown to release growth hormone (GH) from somatotrophs in the adenohypophysis.8 Indeed, a ghrelin challenge is known to raise serum concentration of GH.5 8-10

According to a number of reports, administration of pharmacological doses of ghrelin to intact animals increases food intake, induces weight gain, and causes obesity.11-16 The orexigenic and body fat promoting properties of ghrelin and GHS are thought to be independent of GH and mediated by the hypothalamic neuropeptide Y and agouti related protein systems.17,18 19-21 As noted above, the effects of pharmacological ghrelin treatment are well documented but the role of endogenous ghrelin is by comparison poorly understood. It has been reported recently that knockout of either the ghrelin gene or the ghrelin receptor gene exerts no or minor effects on body growth and body composition.20-22 However, the lack of phenotypic changes in knockout mice may reflect compensatory mechanisms, manifested already during embryonic development, a stage characterised by great plasticity. This problem may be avoided by depleting animals of ghrelin during adult life.

In humans, gastrectomy (Gx) results in loss of body weight of about 10% within the first six months after surgery, mainly due to reduced body fat.23 In addition, Gx patients often complain of fatigue and loss of appetite and several reports describe impaired bone quality (osteopenia/osteomalacia).24-28 At present there is no satisfactory treatment for any of these symptoms. In rats, Gx is associated with bone loss (compared with controls) while body weight is affected marginally, if at all.29-31 On the whole, the effects of Gx on food intake and body composition (other than bone) have been poorly documented in rodents.

In rats and humans, more than 80% of circulating ghrelin is lost following surgical removal of the glandular stomach or the acid producing part of the stomach21,22 and we predict a similar reduction in Gx mice. The postulated adipogenic and anabolic effects of ghrelin prompted us to investigate whether the effects of Gx can be reversed by long term ghrelin treatment in mice.

METHODS

Chemicals

In all, 55 mg of octanoylated ghrelin-28 was made available for the study through collection of ghrelin from three different sources. During the first four weeks of the study, we used rat ghrelin, kindly donated by Professor Chizuka Yanaihara at the Yanaihara Institute, Shizuoka, Japan. In the following two weeks mice were treated with rat ghrelin from Innovagen, Lund, Sweden (custom synthesis), and

Abbreviations: Gx, gastrectomy; GH, growth hormone; GHS, growth hormone secretagogue; BMD, bone mineral density; IGF-1, insulin-like growth factor 1
subsequently (the two last weeks) they received human ghrelin, kindly provided by Dr Matthias Tschöp (University of Cincinnati, Cincinnati, Ohio, USA). Each batch of ghrelin was tested for purity by high pressure liquid chromatography and for bioactivity by measuring the effects of a single subcutaneous injection of 10 μg (3 nmol) ghrelin on gastric emptying or rise in plasma GH concentration. Ghrelin was dissolved in 0.9% saline (sterile); fresh solutions were prepared daily.

**Animals**
Female NMRI mice (aged 8–9 weeks) were obtained from B&K (Sollentuna, Sweden). They were kept in groups of three in plastic cages in a temperature controlled environment (21°C) on a 12 hour light/dark cycle, with free access to standard food pellets (Lactamin, Vadstena, Sweden) and tap water. They were allowed to acclimatise for a week before surgery. At the time of surgery body weight was approximately 33 g. Body weights were determined every week thereafter. The experiments were approved by the local animal welfare committee, Lund, Sweden.

**Selection of the ghrelin dose**
In a pilot study, intact mice received 12 nmol (n = 6) or 24 nmol (n = 6) of ghrelin in 0.9% saline by a subcutaneous bolus injection in the neck (corresponding to 400 and 800 nmol/kg, respectively). Small blood samples (25 μl) were drawn repeatedly by retro-orbital venepuncture before (time 0) and 15, 60, 120, 240, and 300 minutes after injection of ghrelin. The ghrelin doses tested were selected based on the report of Tschöp et al (2.4 μmol/kg). After demonstrating that both 12 and 24 nmol of ghrelin generated blood levels in excess of physiological concentrations for more than 16 hours after injection, we selected a dose of 12 nmol. The purpose of the study was to replace ghrelin that was lost after Gx using doses that generated near physiological plasma concentrations; there was no intent to induce sustained supraphysiological plasma concentrations of ghrelin. The dose of 12 nmol was found to satisfy these requirements.

**Surgery**
Mice were randomly subjected to Gx (26 mice) or sham operation (22 mice). They were anaesthetised with an intraperitoneal injection of a mixture of fluanisone/fentanyl/midazolam (15/0.5/7.5 mg/kg). Gastric surgery was performed through a midline abdominal incision with clean but not sterile instruments. No antibiotics were used. Gx was carried out by resection of the stomach, followed by anastomosis of the oesophagus with the duodenum, end to end. The procedure of Gx includes bilateral subdiaphragmatic vagotomy. Two of the 26 Gx mice died during the first week after surgery (that is, before ghrelin treatment started). Sham operation consisted of a midline abdominal incision and gentle manipulation of the stomach. There was no mortality in this group. Mice were allowed to recover from surgery for about a week before starting treatment with ghrelin or vehicle.

**Study design**
The study comprised 24 Gx mice and 22 sham operated mice. Twelve Gx mice and 12 sham operated mice received a subcutaneous dose of ghrelin (12 nmol) daily for eight weeks. Twelve Gx mice and 10 sham operated mice received daily injections of saline for eight weeks. On the first 14 days, injections were given in the morning (8–9 am) and subsequent injections were made in the afternoon (5–6 pm).

![Figure 1](https://example.com/figure1.png)

**Figure 1** Plasma concentrations of total and active (octanoylated) ghrelin. A single subcutaneous injection (arrow) of either 12 or 24 nmol of ghrelin to intact mice promptly raised plasma concentrations of total [A] and active [B] ghrelin (n = 6 in each group). Plasma concentrations of total and active ghrelin were low following gastrectomy (Gx) compared with sham operation in mice. Concentrations of total ghrelin (C) and active (D) ghrelin remained elevated 16 hours after injection of 12 nmol of ghrelin after sham operation or gastrectomy in mice. Values are means (SEM); n = 10–12. *p<0.05, **p<0.01, ***p<0.001.
Daily food intake in these animals was calculated as the difference between the amount of food given and the amount of food that remained after 24 hours. Cumulative body weight gain was based on weekly determinations of body weights and expressed as body weight minus weight at the start of ghrelin treatment for each mouse. After eight weeks of treatment with ghrelin or saline, mice were killed by decapitation (16–18 hours after the last injection). Blood was collected from the neck and plasma prepared (see below). White adipose tissue (mesenteric, retroperitoneal, parametrial, and inguinal) was dissected out and weighed. Lean tissue and bone mineral density (BMD) were assessed (whole mouse) by dual energy absorptiometry (DEXA; PIXImus, Lunar Corporation, Madison, Michigan, USA). Femurs were collected and their lengths measured after which they were incinerated for 24 hours at 600°C. Ash weight was determined.

**Measurement of circulating ghrelin and insulin-like growth factor 1 (IGF-1)**

Concentrations of circulating ghrelin and IGF-1 were determined in plasma from animals at sacrifice (end point analysis). Blood samples were collected and plasma prepared according to the respective manufacturer’s protocol.

**Total ghrelin**

Immunoreactive ghrelin was measured in 5–20 μl of plasma using a commercial radioimmunoassay kit (Phoenix Pharmaceuticals, Belmont, California, USA) with an antisemur raised against acylated human ghrelin; 125I labelled ghrelin-28 was used as tracer and rat ghrelin-28 as standard. The antisemur recognises both octanoylated and des-octanoylated ghrelin-28 but does not recognise des-Gln14 ghrelin. Plasma concentrations were expressed as pmol equivalents of rat ghrelin-28 per litre. The detection limit for total ghrelin is 12 fmol/l. Intra- and interassay variation was 3% and 8%, respectively.

**Active ghrelin**

Active (octanoylated) ghrelin was determined in 50 μl of plasma using an enzyme linked immunosorbent assay kit (Linco Research, St Charles, Missouri, USA). The antisemur does not recognise des-octanoylated ghrelin. The detection limit for active ghrelin is 1 pmol/l. Intra- and inter assay variation was 3% and 4%, respectively.

**IGF-1**

Plasma IGF-1 was measured in 10 μl of plasma with a radioimmunoassay kit from Medagnost (Reutlingen, Germany). The sensitivity of this assay is 0.02 nmol/l.

**Statistical analysis**

Values are expressed as means (SEM). Differences were analysed statistically using the Student’s unpaired t test or by analysis of variance (ANOVA) followed by Tukey-Kramer’s test, where appropriate (continuous measurements). A p value of <0.05 was considered statistically significant. The half-life of ghrelin in the circulation was calculated based on the curve showing plasma concentrations following a single ghrelin injection (fig 1) (GraphPad Prism version 3.0; GraphPad Software, San Diego, California, USA). Correlation between total and active ghrelin was calculated by Pearson’s linear regression test.

**RESULTS**

**Plasma concentrations of ghrelin**

A single subcutaneous injection of either 12 or 24 nmol of ghrelin to intact mice promptly raised the circulating concentration of total (active octanoylated and inactive des-octanoylated) ghrelin, with a peak value after 15–60 minutes (fig 1A). Five hours after injection of either dose, circulating total ghrelin concentration was markedly decreased compared with the peak value but was still higher than the ghrelin concentration before injection (12 nmol dose: 0.6 (0.07) v 2.1 (0.4) nmol/l; 24 nmol dose: 0.8 (0.09) v 7.1 (2.5) nmol/l). Plasma concentrations of active (octanoylated) ghrelin showed a similar time course (fig 1B); five hours after injection of 12 nmol ghrelin, concentrations were still much higher than before injection (19.5 (1.6) v 570 (149) pmol/l). The half lives of total and active ghrelin were calculated from the data in fig 1A and 1B and found to be 85 and 105 minutes, respectively.

Circulating concentrations of total and active ghrelin were greatly reduced by Gx (measured eight weeks after surgery). Correlation between total and active ghrelin was calculated by Pearson’s linear regression test.
operation) (fig 1C, 1D). Sixteen hours after injection of ghrelin (12 nmol), plasma concentrations (total and active ghrelin) remained elevated compared with after saline injection in both Gx and sham operated animals (fig 1C, 1D). There was a positive correlation between levels of circulating total and active ghrelin ($r = 0.54$; $p<0.008$, $n = 6$).

**Food intake**

Daily food intake, expressed as g/individual, did not differ between Gx and sham operated mice, and there was no difference in daily food intake between mice receiving a daily dose of ghrelin and those receiving saline (fig 2A). Daily food intake, expressed as g/g body weight, did not differ between the groups: 9.7 (0.6) for Gx mice, 8.8 (0.7) for sham operated mice, 8.9 (0.7) in ghrelin treated Gx mice, and 7.9 (0.4) in ghrelin treated sham operated mice ($p>0.05$). Cumulative food intake, expressed as g/individual over time, was similar in sham operated and Gx mice, and ghrelin treatment did not affect cumulative food intake in either sham operated ($p = 0.28$) or Gx ($p = 0.78$) mice (fig 2B).

**Weight gain**

Mean body weight was lower in GX mice three weeks after surgery, continuing until nine weeks after surgery, than in sham operated mice. Nine weeks after surgery, body weight of Gx mice was 15% lower than in sham operated controls ($p<0.001$) (fig 3). Daily injections of ghrelin to Gx mice raised body weight (compared with saline treated Gx mice); the relative weight increase was 8% after eight weeks of treatment ($p<0.001$) (fig 4B). Most of the difference in cumulative body weight gain between ghrelin and saline treated Gx animals occurred during the first two weeks of treatment (fig 4D). Cumulative body weight gain in Gx mice was increased by eight weeks of ghrelin treatment compared with Gx mice receiving saline (5.4 (0.7) v 1.1 (0.8) g; $p<0.001$) (fig 4D). In contrast, body weight and cumulative body weight gain in sham operated mice were only significantly affected by ghrelin two weeks after initiation of treatment and this difference diminished with time (fig 4A, C). Ghrelin did not affect plasma levels of GH dependent IGF-1 or femur length in either Gx or sham operated mice ($p>0.05$) (table 1).

**Body composition**

**Fat depots**

Gx reduced the total weight of four different fat depots by approximately 30% ($p<0.01$) compared with sham operation. Daily administration of ghrelin normalised the total amount of fat in Gx mice ($p = 0.95$; Gx+ghrelin v sham+saline) and raised it by 20% ($p<0.05$) in sham operated animals (fig 5A).

---

**Table 1** Lack of effect of ghrelin (versus saline) on femur bone length and plasma insulin-like growth factor 1 (IGF-1) concentration after sham operation or gastrectomy (Gx) in mice

<table>
<thead>
<tr>
<th></th>
<th>Sham+saline</th>
<th>Sham+ghrelin</th>
<th>p Value</th>
<th>Gx+saline</th>
<th>Gx+ghrelin</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Length of femur (mm)</strong></td>
<td>17.3 (0.2)</td>
<td>16.9 (0.2)</td>
<td>0.30</td>
<td>17.0 (0.1)</td>
<td>16.9 (0.1)</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Plasma IGF-1 (nmol/l)</strong></td>
<td>53 (3.7)</td>
<td>54.1 (1.5)</td>
<td>0.78</td>
<td>52.1 (2.2)</td>
<td>53.8 (2.5)</td>
<td>0.56</td>
</tr>
</tbody>
</table>

Duration of the study was eight weeks.
Values are means (SEM); $n = 10–12$.
$p$ values refer to differences between saline and ghrelin treatments.
Ghrelin replacement in gastrectomised mice

The effect of ghrelin on individual fat depots was not statistically significant (table 2).

**Lean body mass**

Gx reduced the amount of lean tissue (−10%; p<0.01) compared with sham operation. Daily administration of ghrelin increased the amount of lean tissue in Gx mice (8%; p<0.05) but had no effect in sham operated mice (p>0.05) (fig 5B).

**Bone mass**

Total BMD and bone ash weight of the femur was lower in Gx mice than in sham operated mice (−20%; p<0.001). Daily administration of ghrelin failed to affect BMD and femur ash weight in either Gx or sham operated mice (fig 5C, D).

**DISCUSSION**

Gx decreased body weight, body fat mass, lean body mass, and bone mass, and was accompanied by greatly reduced circulating concentrations of total and active ghrelin (−80% decrease), raising the possibility that the effects of Gx on body composition are due to hypogrehelinaemia. Ghrelin has been put forward as a signal stimulating food intake, body weight gain, and fat deposition. In the present study, ghrelin increased body fat but had no effect on daily food intake, weight gain, lean body mass, or bone mass in sham operated mice. In Gx mice, however, daily ghrelin injections, resulting in hyperghrelinaemia, partly prevented the reduction in body weight, lean body mass, and fat mass without affecting daily food intake and bone mass. The hypothesis originally put forward by Cummings and colleagues that ghrelin deficiency contributes to the loss of fat in patients after gastric bypass surgery is in line with our results suggesting that ghrelin helps retain body fat (and possibly lean body mass) in mice. The previously reported absence of deficiency symptoms in knockout mice, lacking ghrelin or ghrelin receptors, could be due to compensatory mechanisms during development. Further studies are needed to clarify the role of ghrelin in the regulation of body composition.

Our results raise the possibility that ghrelin replacement therapy can reverse some of the symptoms associated with Gx in humans. Therapeutic Gx in humans is associated with osteopathy, loss of body weight and body fat, as well as

**Table 2** Effect of ghrelin (versus saline) on the weight of individual fat depots after sham operation or gastrectomy (Gx) in mice

<table>
<thead>
<tr>
<th>Fat depot</th>
<th>Sham+saline</th>
<th>Sham+ghrelin</th>
<th>p Value</th>
<th>Gx+saline</th>
<th>Gx+ghrelin</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesenteric</td>
<td>0.5 (0.06)</td>
<td>0.6 (0.07)</td>
<td>0.072</td>
<td>0.4 (0.04)</td>
<td>0.5 (0.04)</td>
<td>0.093</td>
</tr>
<tr>
<td>Retroperitoneal</td>
<td>0.4 (0.08)</td>
<td>0.6 (0.1)</td>
<td>0.40</td>
<td>0.3 (0.04)</td>
<td>0.4 (0.04)</td>
<td>0.12</td>
</tr>
<tr>
<td>Parametral</td>
<td>0.6 (0.1)</td>
<td>0.8 (0.2)</td>
<td>0.22</td>
<td>0.5 (0.07)</td>
<td>0.7 (0.08)</td>
<td>0.36</td>
</tr>
<tr>
<td>Inguinal</td>
<td>0.7 (0.2)</td>
<td>0.9 (0.2)</td>
<td>0.02</td>
<td>0.5 (0.06)</td>
<td>0.8 (0.1)</td>
<td>0.60</td>
</tr>
</tbody>
</table>

Duration of the study was eight weeks.

Values are means (SEM); n = 10–12.

*p values refer to differences between saline and ghrelin treatments.
fatigue and decreased quality of life.35–38 At present, there are no generally accepted treatments for the catabolic effects of Gx. In mice, Gx resulted in a reduction in body weight and in the amount of lean tissue, bone, and fat compared with sham operation. Therefore, Gx mice may serve as a model for the clinical symptoms associated with Gx in patients although Gx mice continued to grow (except during the first two postoperative weeks) and hence cannot be described as catabolic.

The ghrelin induced weight gain in Gx mice relative to saline injected Gx mice was particularly apparent during the first two weeks of treatment, after which time most of the gastric emptying evoked weight loss had been reversed. Previous studies have shown that the stimulatory effect of ghrelin or ghrelin analogues on body weight in intact mice plateaus after approximately 2–6 weeks,18 19 possibly because the animals have reached a new set point for body weight at that time.

The present finding that ghrelin treatment enhanced body weight and body fat mass in Gx mice (that were also vagotomised) is interesting in view of the fact that subdiaphragmatic vagotomy per se has been reported to prevent the meal initiating effect of ghrelin.18 19 Conceivably, vagotomy impairs ghrelin stimulated meal initiation but not the long term effects of ghrelin on body fat. In the present study we did not investigate the effects of ghrelin in animals that were vagotomised only, but the fact that ghrelin was more effective in Gx (and vagotomised) mice than in vagally intact mice suggests that vagotomy does not prevent ghrelin from stimulating fat deposition.

The simplest interpretation of our data seems to be that endogenous ghrelin contributes to maintain body fat (and indirectly body weight). Low levels of circulating ghrelin in Gx mice appeared to contribute to loss of body fat and body weight, as these effects were alleviated by ghrelin treatment. Although ghrelin increased body fat in both Gx and sham operated mice, ghrelin affected body weight in Gx mice but not in sham operated mice. Tschöp and colleagues17 observed an effect of ghrelin on both body weight and body fat in intact mice; the ghrelin dose was six times higher than that in the present study (2.4 v 0.4 μmol/kg). However, the fact that ghrelin treatment in this study resulted in substantially higher than normal blood levels of ghrelin for a large part of the day would seem to disagree with the interpretation that our treatment protocol was suboptimal. However, we could only partly reverse the Gx induced decrease in body weight. This could be due to the fact that Gx causes defects other than ghrelin deficiency, such as loss of ability to ingest large amounts of food or loss of other, as yet unidentified, gastric hormones. In any case, the Gx model may be complementary to ghrelin and ghrelin receptor knockout models20–22 by providing information about the effects of hypoghlrelinaeinma in adult animals.

The plasma concentration of active (octanoylated) ghrelin was much lower than that of total (octanoylated+des-octanoylated) ghrelin. The ratio of active versus total ghrelin was similar in different individuals and in different experimental groups, in line with other studies.39 This finding increases the likelihood that our measurements of active ghrelin reflect true values, assuming that the concentration of total ghrelin is proportional to that of active ghrelin.

Ghrelin did not stimulate daily food intake (see also Tschöp and colleagues17) in either intact or Gx mice, which is in line with the view that the postulated stimulatory effect of ghrelin is restricted to the first few hours after injection of the hormone (meal initiation).18 Our observation that ghrelin increases body weight and body fat in Gx mice without affecting daily food intake could suggest that rather than causing hyperphagia, ghrelin suppresses energy metabolism, but further studies are needed to confirm this. However, this is in line with the view of Tschöp and colleagues17 that ghrelin exerts long term effects on energy balance in intact mice by increasing the respiratory quotient, suggesting increased utilisation of carbohydrates and decreased utilisation of fat as an energy source. Interestingly, Wortley and colleagues22 recently showed that ghrelin knockout mice had unchanged food intake (but displayed a decreased respiratory quotient on a high fat diet), supporting the notion that the long term effects of endogenous ghrelin on body composition are mediated by changes in fuel preference rather than in food intake. In humans, the results of several studies have indicated a negative correlation between circulating ghrelin levels and energy expenditure.36 37

Our finding that administration of ghrelin increased body fat mass (despite the well known lipolytic effect of GH) without affecting daily food intake, femur length, or plasma IGF-1 suggests that the effect does not reflect an action in the hypothalamus-hypophysis causing GH mobilisation. Neither do our results support the view that circulating ghrelin acts on fat (and body weight) via the vagus (since Gx mice responded to ghrelin). Hence the site of the lipogenic action of ghrelin is not known. Although AgRP/NPY neurones of the arcuate nucleus17 38 represent a possible target for circulating ghrelin, it is perhaps more likely that ghrelin acts by a peripheral mechanism. Indeed, ghrelin has been suggested to exert lipogenic effects directly on adipocytes.39 40 Gx does not affect plasma concentrations of glucose, insulin, or glucagon in freely fed mice.41 However, Gx affects pancreatic islet function in that Gx mice display an impaired insulin (and glucagon) response to oral as well as intravenous glucose and reduced glucose tolerance.42 Although there were no abnormalities in serum lipids in Gx mice,42 it cannot be excluded that the Gx evoked impairment of pancreatic islet function may contribute to loss of fat. Within the physiological plasma concentration range, ghrelin seems to have modest effects on circulating levels of insulin and glucose.43

Gx decreased bone mineral density and bone ash weight of the femur compared with sham operated mice. This is in line with earlier studies of rats, showing that the acid producing part of the stomach is required to maintain a normal skeleton.40–43 It has been suggested that as yet unidentified hormones in the oxyntic mucosa promote the growth and development of trabecular bone by ensuring proper utilisation of circulating Ca2+44. Also, GH is thought to be important for normal bone growth.45 Therefore, ghrelin, being a powerful GH secretagogue, is a candidate for the proposed bone preserving hormone in the stomach. However, as ghrelin treatment did not affect bone in sham operated mice and did not reverse the effect of Gx on bone, the present results do not support the idea that ghrelin deficiency can explain the Gx evoked osteopenia.

In conclusion, our findings suggest that ghrelin treatment can reverse the reduction in body fat and body weight observed in Gx mice. These results are in line with a physiological role of ghrelin in the regulation of body composition (notably fat), raising the possibility that ghrelin replacement therapy may alleviate some of the clinical symptoms of Gx in humans.

ACKNOWLEDGEMENTS

We are grateful to Dr Peter Höglund, Lund University Hospital, for statistical guidance, and Britt Carlsson and Anna Themner-Persson for expert technical assistance. This study was supported by grants from the Swedish Research Council (04x-1007, 04x-14610 and 521-2003-5116), the A Pålsson Foundation, the Novo Nordisk Foundation, the Frederik Paulsen Foundation, the Medical Faculty of Lund University, the 6th framework (LSHM-CT-2003-503041), Swedish Medical Research Council (2003-04-14610-01A), and the Medical Research Council (UK).
Conflict of interest: declared.

REFERENCES


